Advertisement

Molecular Medicine

, Volume 18, Issue 2, pp 186–193 | Cite as

Ghrelin Attenuates Brain Injury after Traumatic Brain Injury and Uncontrolled Hemorrhagic Shock in Rats

  • Lei Qi
  • Xiaoxuan Cui
  • Weifeng Dong
  • Rafael Barrera
  • Jeffrey Nicastro
  • Gene F. Coppa
  • Ping Wang
  • Rongqian Wu
Research Article

Abstract

Traumatic brain injury (TBI) and hemorrhagic shock often occur concomitantly due to multiple injuries. Gastrointestinal dysfunction occurs frequently in patients with TBI. However, whether alterations in the gastrointestinal system are involved in modulating neuronal damage and recovery after TBI is largely neglected. Ghrelin is a “gut-brain” hormone with multiple functions including antiinflammation and antiapoptosis. The purpose of this study was to determine whether ghrelin attenuates brain injury in a rat model of TBI and uncontrolled hemorrhage (UH). To study this, brain injury was induced by dropping a 450-g weight from 1.5 m onto a steel helmet attached to the skull of male adult rats. Immediately after TBI, a midline laparotomy was performed and both lumbar veins were isolated and severed at the junction with the vena cava. At 45 min after TBI/UH, ghrelin (4, 8 or 16 nmol/rat) or 1 mL normal saline (vehicle) was intravenously administered. Brain levels of TNF-α and IL-6, and cleaved PARP-1 levels in the cortex were measured at 4 h after TBI/UH. Beam balance test, forelimb placing test and hindlimb placing test were used to assess sensorimotor and reflex function. In additional groups of animals, ghrelin (16 nmol/rat) or vehicle was subcutaneously (s.c.) administered daily for 10 d after TBI/UH. The animals were monitored for 28 d to record body weight changes, neurological severity scale and survival. Our results showed that ghrelin downregulated brain levels of TNF-α and IL-6, reduced cortical levels of cleaved PARP-1, improved sensorimotor and reflex functions, and decreased mortality after TBI/UH. Thus, ghrelin has a great potential to be further developed as an effective resuscitation approach for the trauma victims with brain injury and severe blood loss.

Notes

Acknowledgments

This study was supported by a DoD/DRMRP Grant DR080669 (R Wu) and an NIH grant R21 NS072608 (R Wu).

References

  1. 1.
    Davis KL, Joshi AV, Tortella BJ, Candrilli SD. (2007) The direct economic burden of blunt and penetrating trauma in a managed care population. J. Trauma 62:622–9.CrossRefGoogle Scholar
  2. 2.
    Boulanger L, et al. (2007) Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma patients: findings from the National Trauma Data Bank. Am. Surg. 73:1269–74.PubMedGoogle Scholar
  3. 3.
    Coronado VG, et al. (2011) Surveillance for traumatic brain injury-related deaths—United States, 1997–2007. MMWR Surveill. Summ. 60:1–32.PubMedGoogle Scholar
  4. 4.
    Wu X, et al. (2008) Epidemiology of traumatic brain injury in eastern China, 2004: a prospective large case study. J. Trauma 64:1313–9.CrossRefGoogle Scholar
  5. 5.
    Katsaragakis S, et al. (2010) Traumatic brain injury in Greece: report of a countrywide registry. Brain Inj. 24:871–6.CrossRefGoogle Scholar
  6. 6.
    Manley G, et al. (2001) Hypotension, hypoxia, and head injury: frequency, duration, and consequences. Arch. Surg. 136:1118–23.CrossRefGoogle Scholar
  7. 7.
    Dewitt DS, Prough DS. (2009) Blast-induced brain injury and posttraumatic hypotension and hypoxemia. J. Neurotrauma. 26:877–87.CrossRefGoogle Scholar
  8. 8.
    Chesnut RM, et al. (1993) The role of secondary brain injury in determining outcome from severe head injury. J. Trauma 34:216–22.CrossRefGoogle Scholar
  9. 9.
    Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–60.CrossRefGoogle Scholar
  10. 10.
    Arvat E, et al. (2000) Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J. Endocrinol. Invest. 23:493–5.CrossRefGoogle Scholar
  11. 11.
    Date Y, et al. (2000) Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem. Biophys. Res. Commun. 275:477–80.CrossRefGoogle Scholar
  12. 12.
    Nass R, et al. (2000) Intracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GH. J. Neuroendocrinol. 12:1194–9.CrossRefGoogle Scholar
  13. 13.
    Cowley MA, Grove KL. (2004) Ghrelin—satisfying a hunger for the mechanism. Endocrinology. 145:2604–6.CrossRefGoogle Scholar
  14. 14.
    Andrews ZB, et al. (2008) UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature 454:846–51.CrossRefGoogle Scholar
  15. 15.
    Wu R, et al. (2008) Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion. PLoS ONE. 3:e2026.CrossRefGoogle Scholar
  16. 16.
    Wu R, et al. (2007) Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann. Surg. 245:480–6.CrossRefGoogle Scholar
  17. 17.
    Wu R, etal. (2007) Ghrelin inhibits sympathetic nervous activity in sepsis. Am. J. Physiol. Endocrinol. Metab. 293:E1697–E1702.CrossRefGoogle Scholar
  18. 18.
    Wu R, et al. (2007) Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am. J. Respir. Crit. CareMed. 176:805–13.CrossRefGoogle Scholar
  19. 19.
    Chung H, et al. (2007) Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. Endocrinol. 148:148–59.CrossRefGoogle Scholar
  20. 20.
    Miao Y, Xia Q, Hou Z, Zheng Y, Pan H, Zhu S. (2007) Ghrelin protects cortical neuron against focal ischemia/reperfusion in rats. Biochem. Biophys. Res. Commun. 359:795–800.CrossRefGoogle Scholar
  21. 21.
    Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P. (2011) Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 35:258–65.CrossRefGoogle Scholar
  22. 22.
    Bansal V, et al. (2010) The hormone ghrelin prevents traumatic brain injury induced intestinal dysfunction. J. Neurotrauma 27:2255–60.CrossRefGoogle Scholar
  23. 23.
    Marmarou A, Foda MA, van den BW, Campbell J, Kita H, Demetriadou K. (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J. Neurosurg. 80:291–300.CrossRefGoogle Scholar
  24. 24.
    Foda MA, Marmarou A. (1994) A new model of diffuse brain injury in rats. Part II: Morphological characterization. J. Neurosurg. 80:301–13.CrossRefGoogle Scholar
  25. 25.
    Wu R, et al. (2007) Adrenomedullin and adreno-medullin binding protein-1 prevent metabolic acidosis after uncontrolled hemorrhage in rats. Crit. Care Med. 35:912–8.CrossRefGoogle Scholar
  26. 26.
    Wu R, Dong W, Zhou M, Cui X, Hank SH, Wang P. (2005) Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc. Res. 68:318–26.CrossRefGoogle Scholar
  27. 27.
    Wu R, et al. (2009) Ghrelin hyporesponsiveness contributes to age-related hyperinflammation in septic shock. Ann. Surg. 250:126–33.CrossRefGoogle Scholar
  28. 28.
    Ziebell JM, Morganti-Kossmann MC. (2010) Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 7:22–30.CrossRefGoogle Scholar
  29. 29.
    Savitz SI, Rosenbaum DM. (1998) Apoptosis in neurological disease. Neurosurgery. 42:555–72.CrossRefGoogle Scholar
  30. 30.
    Chaitanya GV, Steven AJ, Babu PP. (2010) PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun. Signal. 8:31.CrossRefGoogle Scholar
  31. 31.
    Medana IM, Esiri MM. (2003) Axonal damage: a key predictor of outcome in human CNS diseases. Brain 126:515–30.CrossRefGoogle Scholar
  32. 32.
    Krakau K, Omne-Ponten M, Karlsson T, Borg J. (2006) Metabolism and nutrition in patients with moderate and severe traumatic brain injury: A systematic review. Brain Inj. 20:345–67.CrossRefGoogle Scholar
  33. 33.
    Wang G, Lee HM, Englander E, Greeley GH, Jr. (2002) Ghrelin—not just another stomach hormone. Regul. Pept. 105:75–81.CrossRefGoogle Scholar
  34. 34.
    Van Der Lely AJ, Tschop M, Heiman ML, Ghigo E. (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25:426–57.CrossRefGoogle Scholar
  35. 35.
    Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki C. (2001) GH, GH receptor, GH secret-agogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J. Clin. Endocrinol. Metab. 86:4284–91.CrossRefGoogle Scholar
  36. 36.
    Sakata I, Yamazaki M, Inoue K, Hayashi Y, Kangawa K, Sakai T. (2003) Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci. Lett. 342:183–6.CrossRefGoogle Scholar
  37. 37.
    Papotti M, et al. (2000) Growth hormone secretagogue binding sites in peripheral human tissues. J. Clin. Endocrinol. Metab. 85:3803–7.PubMedGoogle Scholar
  38. 38.
    Shuto Y, et al. (2001) Generation of polyclonal antiserum against the growth hormone secretagogue receptor (GHS-R): evidence that the GHS-R exists in the hypothalamus, pituitary and stomach of rats. Life Sci. 68:991–6.CrossRefGoogle Scholar
  39. 39.
    Kojima M, Kangawa K. (2005) Ghrelin: structure and function. Physiol. Rev. 85:495–522.CrossRefGoogle Scholar
  40. 40.
    Bansal V, et al. (2012) Vagal stimulation modulates inflammation through a ghrelin mediated mechanism in traumatic brain injury. Inflammation. 35:214–20.CrossRefGoogle Scholar
  41. 41.
    Wu R, et al. (2009) Ghrelin hyporesponsiveness contributes to age-related hyperinflammation in septic shock. Ann. Surg. 250:126–33.CrossRefGoogle Scholar
  42. 42.
    Ammori JB, Zhang WZ, Li JY, Chai BX, Mulholland MW. (2008) Effects of ghrelin on neuronal survival in cells derived from dorsal motor nucleus of the vagus. Surgery 144:159–67.CrossRefGoogle Scholar
  43. 43.
    Cederberg D, Siesjo P. (2010) What has inflammation to do with traumatic brain injury? Childs Nerv. Syst. 26:221–6.CrossRefGoogle Scholar
  44. 44.
    Wong J, Hoe NW, Zhiwei F, Ng I. (2005) Apoptosis and traumatic brain injury. Neurocrit. Care 3:177–82.CrossRefGoogle Scholar
  45. 45.
    Luo C, Jiang J, Lu Y, Zhu C. (2002) Spatial and temporal profile of apoptosis following lateral fluid percussion brain injury. Chin. J. Traumatol. 5:24–7.PubMedGoogle Scholar
  46. 46.
    Clark RS, et al. (1999) Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. FASEB J. 13:813–21.CrossRefGoogle Scholar
  47. 47.
    Dressler J, Hanisch U, Kuhlisch E, Geiger KD. (2007) Neuronal and glial apoptosis in human traumatic brain injury. Int. J. Legal Med. 121:365–75.CrossRefGoogle Scholar
  48. 48.
    Kelly DF, et al. (2006) Neurobehavioral and quality of life changes associated with growth hormone insufficiency after complicated mild, moderate, or severe traumatic brain injury. J. Neurotrauma 23:928–42.CrossRefGoogle Scholar
  49. 49.
    Sangiao-Alvarellos S, Cordido F. (2010) Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications. Int. J. Pept. 2010:234709.CrossRefGoogle Scholar
  50. 50.
    Dezaki K, Sone H, Yada T. (2008) Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118:239–49.CrossRefGoogle Scholar
  51. 51.
    Bilotta F, Giovannini F, Caramia R, Rosa G. (2009) Glycemia management in neurocritical care patients: a review. J. Neurosurg. Anesthesiol. 21:2–9.CrossRefGoogle Scholar
  52. 52.
    Jacka MJ, Torok-Both CJ, Bagshaw SM. (2009) Blood glucose control among critically ill patients with brain injury. Can. J. Neurol. Sci. 36:436–42.CrossRefGoogle Scholar
  53. 53.
    Godoy DA, Di NM, Rabinstein AA. (2010) Treating hyperglycemia in neurocritical patients: benefits and perils. Neurocrit. Care 13:425–38.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Lei Qi
    • 1
    • 2
    • 3
  • Xiaoxuan Cui
    • 1
    • 2
  • Weifeng Dong
    • 1
    • 2
  • Rafael Barrera
    • 2
  • Jeffrey Nicastro
    • 2
  • Gene F. Coppa
    • 2
  • Ping Wang
    • 1
    • 2
  • Rongqian Wu
    • 1
    • 2
  1. 1.Laboratory of Surgical ResearchThe Feinstein Institute for Medical ResearchManhassetUSA
  2. 2.Department of SurgeryNorth Shore University Hospital and Long Island Jewish Medical CenterManhassetUSA
  3. 3.Department of Neurosurgery, First Affiliated Hospital of Medical SchoolXi’an Jiaotong UniversityXi’an, ShaanxiChina

Personalised recommendations